SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies
Sodium-glucose cotransporter inhibitors (SGLT2i) play an increasingly important role in type 2 diabetes mellitus (T2DM) due to their significant cardiovascular benefits and renal protection in addition to their hypoglycemic effects. In recent years, the application of SGLT2i in patients with type 1...
Main Authors: | Yujin Ma, Qian Zhao, Huifang Peng, David Lubasi Nalisa, Pengfei Shan, Hongwei Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
IMR Press
2023-05-01
|
Series: | Frontiers in Bioscience-Landmark |
Subjects: | |
Online Access: | https://www.imrpress.com/journal/FBL/28/5/10.31083/j.fbl2805098 |
Similar Items
-
Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis
by: Siddhartha Dutta, et al.
Published: (2022-01-01) -
Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report
by: Felice Nappi, et al.
Published: (2019-08-01) -
Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems—A Literature Review
by: Viviana Elian, et al.
Published: (2024-02-01) -
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
by: Yi-Chou Hou, et al.
Published: (2020-10-01) -
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
by: Yuta Suzuki, et al.
Published: (2022-05-01)